Mizuho lowered the firm’s price target on Staar Surgical to $58 from $65 and keeps a Buy rating on the shares. The analyst lower targets on several medical technology names ahead of the Q3 earnings season to reflect inputs from hospital/physician surveys and key opinion leader channel checks. The target drops account for the sharp intra-quarter contraction driven in part by GLP-1 risk concerns, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STAA:
- Fly Insider; STAAR Surgical, Blade Air among week’s notable insider trades
- Insider Trading: Staar Surgical’s (NASDAQ:STAA) Major Insider on a Buying Spree
- Needham medtech/diagnostics analysts hold analyst/industry conference call
- Staar Surgical price target lowered to $40 from $45 at Stifel
- Shake Shack upgraded, DoorDash downgraded: Wall Street’s top analyst calls
